Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimization work for its lead OpRegen program.
Chief Executive Officer Brian Culley said the company’s strategy, which it calls “Lineage 3.0,” centers on using its AlloSCOPE manufacturing platform to develop allogeneic, or off-the-shelf, cell therapies that can be produced consistently at scale. Culley said the company aims to target indications where small initial trials could generate meaningful treatment signals and where Lineage can retain improved economics through internal development or partnerships.
AlloSCOPE Manufacturing Focus
Culley said Lineage has established a two-tier current good manufacturing practice banking and production system that it believes can produce millions of vials of a product candidate. Material from those banks has been cleared by the FDA and used in the OpRegen clinical trial, he said.
The company believes the platform can support production costs in the hundreds of dollars per dose, compared with potentially much higher costs for autologous therapies. Culley emphasized that cell-therapy manufacturing requires reproducibility, purity, potency and scalability, and said changes to a production process after early clinical trials can create regulatory and comparability risks.
During the question-and-answer session, Culley declined to provide more detailed information on the vessel sizes used in the company’s Type 1 diabetes manufacturing work, citing the proprietary nature of the process. He said Lineage’s approach is to establish a scalable manufacturing process early rather than modify it later after clinical data are obtained.
Preclinical Pipeline Updates
Lineage’s wholly owned COR1 program is being developed as a corneal endothelial cell therapy for Fuchs’ dystrophy and other corneal endothelial diseases. The company began evaluating the program in the second quarter of 2025 and initiated laboratory work in the third quarter of that year.
According to Culley, Lineage has applied its AlloSCOPE 5D technology to expand precursor cells in bioreactors and differentiate them into corneal endothelial cells. Preclinical in vivo testing is expected to begin imminently, with initial internal animal data targeted by year-end. The company plans to evaluate whether its cells perform at least as well as cadaver-derived cells in established efficacy models.
Culley said the program addresses supply and shelf-life limitations in donor-derived corneal transplants. He cited an estimate of one donor for every 70 diseased eyes globally and noted that donor-derived material must be used promptly rather than cryopreserved. In response to an analyst question, Culley said the existing clinical and regulatory precedent for corneal endothelial cell replacement could allow Lineage to move relatively quickly, although he did not provide a timetable for a clinical filing.
For Type 1 diabetes, Lineage is pursuing ILT1, a manufacturing-focused initiative intended to produce homogeneous populations of undifferentiated pluripotent cells that can serve as source material for islet-cell differentiation. Culley said islet-cell doses may require as many as 1 billion cells per patient and that islet cells do not readily expand during differentiation or in mature form.
The company previously demonstrated a suspension-based process for undifferentiated pluripotent cells at a half-liter scale and has since shown the process in a larger multi-tier format. Its next objective is to demonstrate that cells expanded through the 5D platform can differentiate into islet precursors. Culley said Lineage may provide another diabetes-program update before year-end.
Lineage also reported progress in ReSonance, its auditory neuronal cell-transplant program for hearing loss. The program is being developed with William Demant Invest, which has agreed to fund up to $12 million toward a preclinical plan intended to support an investigational new drug application or clinical trial application filing. The company has completed three engineering runs and its first GMP run, which is undergoing release testing. It is also establishing a deafening model for functional animal testing.
OPC1 and OpRegen Developments
For OPC1, Lineage is considering prioritizing chronic spinal cord injury patients for future development. Culley said chronic patients have more stable neurological baselines than subacute patients, who can experience spontaneous improvements during the months following injury. He also said chronic patients are more prevalent and have longer eligibility windows for enrollment.
The ongoing DOSED study is designed to evaluate the safety and performance of a new delivery device for OPC1. Culley said no unexpected procedural, product-related or device-related adverse events have occurred and no significant device design changes have been required. Priyantha Herath, senior vice president and head of clinical, said two chronic patients have been treated, with one having completed one year of follow-up and the other reaching 90 days. He said both remained stable and adverse-event-free.
Herath cautioned that DOSED was not designed to assess functional efficacy. While he noted anecdotal reports from family members involving breathing and core-strength improvements, he said Lineage would not formally assess neurological changes until an efficacy-focused study. The first four patients in the protocol require a one-month data safety monitoring board pause between enrollments, and the company is assessing candidates for a third patient.
OpRegen, Lineage’s retinal pigment epithelial cell therapy for geographic atrophy associated with dry age-related macular degeneration, remains under development by Roche and Genentech. Culley said the partners are evaluating surgical methods and devices intended to improve safe, reliable delivery to the target lesion in the subretinal space.
He cited expansion of the GAlette study from six to 17 sites beginning last year and OpRegen’s registration in the European Medicines Agency’s IRIS database. Culley characterized the latter as an administrative step required before certain Europe-related product activities, rather than a commitment to conduct studies there.
Lineage remains eligible for up to $615 million in development and commercial milestones under its Roche and Genentech agreement, as well as tiered double-digit royalties. Culley said the agreement is not a co-promotion arrangement.
Financial Results and Cash Runway
Chief Financial Officer Jill Howe said Lineage ended the second quarter with $50.8 million in cash equivalents and marketable securities, which the company expects will fund planned operations into the third quarter of 2028. The projection is one quarter longer than its prior estimate.
The extension reflected approximately $4.6 million raised through the company’s at-the-market facility on June 26, when Lineage was added to the Russell 3000 Index. The shares were sold at a weighted average price of $1.28 each, Howe said.
- Total revenue was $1.1 million, down from $2.8 million in the prior-year quarter, primarily due to lower collaboration revenue under the Roche agreement and lower revenue following the prior-year termination of the VAC collaboration agreement.
- Research and development expense increased to $4.8 million from $3.1 million, driven by preclinical and undisclosed programs.
- General and administrative expense rose to $5.2 million from about $4.5 million, reflecting personnel costs and stock-based compensation.
- Operating loss narrowed to $8.9 million from $19.8 million a year earlier, largely because the prior-year period included a $14.8 million non-cash impairment charge related to the VAC platform.
- Net income was $1.5 million, or $0.01 per basic share, compared with a net loss of $30.5 million, or $0.13 per share, a year earlier.
Howe said the quarterly net-income result primarily reflected a non-cash gain from the fair-value remeasurement of warrant liabilities as Lineage’s share price declined from the prior quarter. She said the accounting adjustment did not represent cash received or used during the quarter.
About Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.
Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Lineage Cell Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lineage Cell Therapeutics wasn't on the list.
While Lineage Cell Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
